Literature DB >> 19501716

Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment.

James M Noble1, Nikolaos Scarmeas.   

Abstract

Alzheimer disease (AD) is the most common type of dementia and will become increasingly prevalent with the growing elderly population. Despite established clinical diagnostic tools, the workup for dementia among primary caregivers can be complicated and specialist referral may not be readily available. A host of AD diagnostic tests has been proposed to aid in diagnosis, including functional neuroimaging such as positron emission tomography (PET). We review the basis for FDG-PET and PiB-PET, as well as available operating statistics. From this we advise scenarios for use of PET in primary settings and referral centers, approach to its interpretation, and outline a clinical prediction model based on findings.

Entities:  

Mesh:

Year:  2009        PMID: 19501716      PMCID: PMC3647230          DOI: 10.1016/S0074-7742(09)00407-3

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  61 in total

1.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

Review 2.  Epidemiology of neurodegeneration.

Authors:  Richard Mayeux
Journal:  Annu Rev Neurosci       Date:  2003-01-24       Impact factor: 12.449

3.  The effect of a memory screening program on the early diagnosis of Alzheimer disease.

Authors:  Warren W Barker; Cheryl Luis; Dylan Harwood; David Loewenstein; Marina Bravo; Ray Ownby; Ranjan Duara
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Jan-Mar       Impact factor: 2.703

4.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

5.  Refining clinical diagnosis with likelihood ratios.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2005 Apr 23-29       Impact factor: 79.321

Review 6.  Cost-effective recognition and diagnosis of dementia.

Authors:  David S Geldmacher
Journal:  Semin Neurol       Date:  2002-03       Impact factor: 3.420

7.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

Review 8.  The role of neuroimaging in mild cognitive impairment.

Authors:  Hiroshi Matsuda
Journal:  Neuropathology       Date:  2007-12       Impact factor: 1.906

9.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

10.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08
View more
  9 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 2.  Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease.

Authors:  Jinghui Dong; Raquel Revilla-Sanchez; Stephen Moss; Philip G Haydon
Journal:  Neuropharmacology       Date:  2010-04-14       Impact factor: 5.250

3.  Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.

Authors:  Christian Habeck; Shannon Risacher; Grace J Lee; M Maria Glymour; Elizabeth Mormino; Shubhabrata Mukherjee; Sungeun Kim; Kwangsik Nho; Charles DeCarli; Andrew J Saykin; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

4.  Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.

Authors:  Ian R Macdonald; Selena P Maxwell; George A Reid; Meghan K Cash; Drew R DeBay; Sultan Darvesh
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease.

Authors:  Drew R DeBay; George A Reid; Ian R Pottie; Earl Martin; Chris V Bowen; Sultan Darvesh
Journal:  Alzheimers Dement (N Y)       Date:  2017-02-24

6.  Caring for older adults with mild cognitive impairment: an update for nurses.

Authors:  Feng Lin; David E Vance; Carey E Gleason; Susan M Heidrich
Journal:  J Gerontol Nurs       Date:  2012-12       Impact factor: 1.254

7.  Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model.

Authors:  Seung-Hoon Yang; Jiyoon Kim; Michael Jisoo Lee; YoungSoo Kim
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379

8.  A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients.

Authors:  Ying Meng; Huiying Li; Rui Hua; Huali Wang; Jian Lu; Xin Yu; Chen Zhang
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379

9.  Cathepsin S Is Involved in Th17 Differentiation Through the Upregulation of IL-6 by Activating PAR-2 after Systemic Exposure to Lipopolysaccharide from Porphyromonas gingivalis.

Authors:  Masato Dekita; Zhou Wu; Junjun Ni; Xinwen Zhang; Yicong Liu; Xu Yan; Hiroshi Nakanishi; Ichiro Takahashi
Journal:  Front Pharmacol       Date:  2017-07-17       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.